par Tuerlinckx, David;Florkin, Benoit;Ferster, Alina 
;De Schutter, Iris;Chantrain, Christophe;Haerynck, Filomeen;Philippet, Pierre;Strengers, Paul;Kupersztejn, Ruth
Référence Pediatrics, 133, 1, page (e154-e162)
Publication Publié, 2014-01
;De Schutter, Iris;Chantrain, Christophe;Haerynck, Filomeen;Philippet, Pierre;Strengers, Paul;Kupersztejn, Ruth Référence Pediatrics, 133, 1, page (e154-e162)
Publication Publié, 2014-01
Article révisé par les pairs
| Résumé : | Clinical data are lacking on optimal levels of specific antipneumococcal antibodies (PnPsAbs) in patients with primary immunodeficiency (PID) receiving intravenous immunoglobulin (IVIG) replacement. Objectives were to conduct a prospective multicenter study providing data on total immunoglobulin G (IgG) and peak/trough levels of PnPsAbs specifically targeting the 16 most prevalent pneumococcal serotypes in IVIG-treated children with PID; to compare trough PnPsAb levels with those measured in healthy adults and the IVIG product; and to evaluate PnPsAb protection correlates with thresholds based on World Health Organization. |
